# Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

> **NCT00609622** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 191 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** sunitinib
- **DRUG:** mFOLFOX6
- **DRUG:** bevacizumab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT00609622
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 191 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2012-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609622, "Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00609622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*